BLRX-BREAKOUT-UPDATE

BLRX had a strong rally today and it's just getting started.

In the related idea my price target was $1.34.

Today's high was $1.78

Check out the weekly chart:

Photo Finish.

$1.34 was 1.618 extension level from Waves 1 & 2.

Since the price-action broke $1.34 we will have an extended 3rd wave.

I expect a very strong rally tomorrow, I will update in the morning before the open to confirm.

Target is hard to predict since its impossible to know what level extending waves will terminate.

I will keep a close eye on the price-action.

Will update.

-AB

코멘트:

As expected, a very strong rally today!

코멘트:

코멘트:

We got a big runway...

코멘트:

Reminder this is a WEEKLY chart...

Meaning this move is far from over...

코멘트:

코멘트:

Buckle up!

코멘트:

코멘트:

Target $2.24 (Sell Half)

Trade Price: 1.049

코멘트:

코멘트:

코멘트:

Bull Flag

코멘트:

BLRX will rally again tomorrow.

코멘트:

코멘트:

BLRX is about to rally again...

코멘트:

BLRX continued to consolidate today.

Staying the course...

코멘트:

코멘트:

코멘트:

Near-Term Target: $2.13

코멘트:

코멘트:

Primary Wave 1 Complete

코멘트:

코멘트:

03:21 PM EDT, 10/22/2018 (MT Newswires) -- Oppenheimer has kept its outperform rating on BioLineRx (BLRX) with a price target of $3, betting on BL-8040's commercial opportunity as a stem cell mobilizer after top-line data from the COMBAT/KEYNOTE-202 trial of BL-8040 in combination with pembrolizumab in advanced pancreatic cancer showed modest response rate.
"Given the combination's favorable safety profile, BioLineRx and Merck (MRK) are testing a triplet combination including chemotherapy in an effort to increase response rate," analyst Mark Breidenbach said in a note.
"While we believe the triplet combination is worth testing, our valuation of BioLineRx still remains focused on BL-8040's commercial opportunity as a stem cell mobilizer."

코멘트:

코멘트:

코멘트:

Breakout Imminent

코멘트: